<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085410</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00046</org_study_id>
    <secondary_id>NCI-2009-00046</secondary_id>
    <secondary_id>CDR0000369715</secondary_id>
    <secondary_id>03-042</secondary_id>
    <secondary_id>03-042</secondary_id>
    <secondary_id>6135</secondary_id>
    <nct_id>NCT00085410</nct_id>
  </id_info>
  <brief_title>Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder</brief_title>
  <official_title>Phase II and Pharmacodynamic Study of PS-341 in Patients With Unresectable or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      This phase II trial is studying how well bortezomib works as first-line systemic therapy in
      treating patients with unresectable locally advanced or metastatic adenocarcinoma (cancer) of
      the bile duct or gallbladder. Bortezomib may stop the growth of tumor cells by blocking the
      enzymes necessary for their growth.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. Determine the objective response rate in patients with unresectable locally advanced or
      metastatic adenocarcinoma of the bile duct or gallbladder treated with bortezomib.

      SECONDARY OBJECTIVES:

      I. Determine the time to disease progression in patients treated with this drug.

      II. Determine the overall survival of patients treated with this drug. III. Correlate the
      degree of proteasome inhibition in peripheral blood with degree of proteasome inhibition in
      tumor specimens of patients treated with this drug.

      IV. Correlate phenotypic expression of NF-kB, p53, and other molecular markers in biliary
      washings and tumor biopsies with clinical outcomes in patients treated with this drug.

      V. Correlate treatment with this drug with changes in phenotypic expression of molecular
      markers in these patients.

      OUTLINE: This is an open-label, multicenter study.

      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every
      21 days in the absence of disease progression or unacceptable toxicity.

      Patients are followed every 3 months for 1 year.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    The trial was discontinued early due to no confirmed partial responses.
  </why_stopped>
  <start_date>January 2004</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">August 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Objective Response Rate (ORR) was determined by best response on radiologic assessment (computed tomography or magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>Time from initiation of therapy to first progressive disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 1 year</time_frame>
    <description>The time from initiation of therapy to death or last follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the Degree of Proteasome Inhibition in Peripheral Blood With the Degree of Proteasome Inhibition in Tumor Specimens</measure>
    <time_frame>Once in the screening period (within 14 days of starting treatment)</time_frame>
    <description>Proteasome inhibition compared between tumor specimens and peripheral blood. Sufficient tissue samples are required for this analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Phenotypic Expression of NF-kB, p53, and Other Molecular Markers in Biliary Washings and Tumor Biopsies With Clinical Outcomes</measure>
    <time_frame>Once in the screening period (within 14 days of starting treatment)</time_frame>
    <description>Evaluation of clinical outcomes with expression of molecular markers specified and others. Sufficient amount of biliary washings and tumor biopsies needed for analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of Treatment With Changes in Phenotypic Expression of Molecular Markers</measure>
    <time_frame>Duration of study treatment</time_frame>
    <description>Phenotypic expression of molecular markers before and after study treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Adenocarcinoma of the Extrahepatic Bile Duct</condition>
  <condition>Adenocarcinoma of the Gallbladder</condition>
  <condition>Advanced Adult Primary Liver Cancer</condition>
  <condition>Gastrointestinal Cancer</condition>
  <condition>Localized Unresectable Adult Primary Liver Cancer</condition>
  <condition>Recurrent Adult Primary Liver Cancer</condition>
  <condition>Recurrent Extrahepatic Bile Duct Cancer</condition>
  <condition>Recurrent Gallbladder Cancer</condition>
  <condition>Unresectable Extrahepatic Bile Duct Cancer</condition>
  <condition>Unresectable Gallbladder Cancer</condition>
  <arm_group>
    <arm_group_label>Arm I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Arm I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Absolute neutrophil count &gt;= 1,500/mm3

          -  No psychiatric illness or social situation that would preclude study compliance

          -  Chemotherapy administered solely as a radiosensitizer or as adjuvant therapy and
             investigational or targeted therapies (i.e., inhibitors of the epidermal growth factor
             receptor) will not count toward the maximum of 2 prior regimens allowed

          -  Histologically or cytologically confirmed adenocarcinoma of the intrahepatic or
             extrahepatic bile duct or gallbladder:

               -  Locally advanced or metastatic disease

          -  At least 1 unidimensionally measurable lesion &gt;=20 mm by conventional techniques OR &gt;=
             10 mm by spiral CT scan

          -  Not amenable to curative surgical resection

          -  No known brain metastases

          -  Performance status:

               -  ECOG 0-2

          -  Life expectancy:

               -  More than 12 weeks

          -  Platelet count &gt;= 100,000/mm3

          -  WBC &gt;= 3,000/mm3

          -  AST and ALT ≤ 2.5 times upper limit of normal (ULN) [Note: Biliary shunting or
             stenting allowed to achieve the required bilirubin and transaminase levels]

          -  Bilirubin ≤ 1.5 times ULN [Note: Biliary shunting or stenting allowed to achieve the
             required bilirubin and transaminase levels]

          -  Creatinine within ULN OR Creatinine clearance &gt;= 60 mL/min

          -  No symptomatic congestive heart failure

          -  No unstable angina pectoris

          -  No symptomatic cardiac arrhythmia within the past 4 weeks

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No underlying neuropathy &gt;= grade 2

          -  No history of allergic reaction to boron, mannitol, or bortezomib

          -  No active or ongoing infection

          -  No concurrent uncontrolled illness

          -  No medical or psychiatric condition that would preclude study participation

          -  No prophylactic granulocyte or platelet growth factors (filgrastim [G-CSF] or
             sargramostim [GM-CSF])

          -  Prior chemotherapy as a radiosensitizer (e.g., fluorouracil or gemcitabine) with
             radiotherapy is allowed as adjuvant therapy after resection for locally advanced
             disease provided there is evidence of disease progression

          -  No more than 2 prior chemotherapy regimens for locally advanced or metastatic disease

          -  No concurrent combination antiretroviral therapy for HIV-positive patients

          -  No other concurrent anticancer agents or therapies

          -  No other concurrent investigational agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Cohen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111-2497</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Denlinger CS, Meropol NJ, Li T, Lewis NL, Engstrom PF, Weiner LM, Cheng JD, Alpaugh RK, Cooper H, Wright JJ, Cohen SJ. A phase II trial of the proteasome inhibitor bortezomib in patients with advanced biliary tract cancers. Clin Colorectal Cancer. 2014 Jun;13(2):81-6. doi: 10.1016/j.clcc.2013.12.005. Epub 2014 Jan 4.</citation>
    <PMID>24512954</PMID>
  </results_reference>
  <verification_date>June 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <results_first_submitted>July 9, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 14, 2017</results_first_posted>
  <last_update_submitted>June 13, 2017</last_update_submitted>
  <last_update_submitted_qc>June 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 2, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
    <mesh_term>Gastrointestinal Neoplasms</mesh_term>
    <mesh_term>Bile Duct Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited through physician referral at: Fox Chase Cancer Center. The trial was discontinued early due to no confirmed partial responses.</recruitment_details>
      <pre_assignment_details>Twenty individuals were enrolled in this study over a four year period.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm I</title>
          <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Arm I</title>
          <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of Primary Tumor</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Gallbladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Intrahepatic or extrahepatic cholangiocarcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Site of Metastases</title>
          <description>Multiple Metastases possible per patient</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymph nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Eastern Cooperative Oncology Group Performance Status</title>
          <description>Grade 0: Fully active, able to carry on all pre-disease performance without restriction
Grade 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Grade 0</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Treatment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy only</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chemotherapy/radiation therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous Surgery</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Yes: Cholecystectomy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes: Liver section</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate</title>
        <description>Objective Response Rate (ORR) was determined by best response on radiologic assessment (computed tomography or magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate</title>
          <description>Objective Response Rate (ORR) was determined by best response on radiologic assessment (computed tomography or magnetic resonance imaging) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0.</description>
          <population>Per protocol</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stable Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response (Unconfirmed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Withdrew Consent Before Evaluation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Time from initiation of therapy to first progressive disease.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Time from initiation of therapy to first progressive disease.</description>
          <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="0.7" upper_limit="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>The time from initiation of therapy to death or last follow-up.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>The time from initiation of therapy to death or last follow-up.</description>
          <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="4.6" upper_limit="18.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of the Degree of Proteasome Inhibition in Peripheral Blood With the Degree of Proteasome Inhibition in Tumor Specimens</title>
        <description>Proteasome inhibition compared between tumor specimens and peripheral blood. Sufficient tissue samples are required for this analysis.</description>
        <time_frame>Once in the screening period (within 14 days of starting treatment)</time_frame>
        <population>Insufficient amount of patient samples collected for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of the Degree of Proteasome Inhibition in Peripheral Blood With the Degree of Proteasome Inhibition in Tumor Specimens</title>
          <description>Proteasome inhibition compared between tumor specimens and peripheral blood. Sufficient tissue samples are required for this analysis.</description>
          <population>Insufficient amount of patient samples collected for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Phenotypic Expression of NF-kB, p53, and Other Molecular Markers in Biliary Washings and Tumor Biopsies With Clinical Outcomes</title>
        <description>Evaluation of clinical outcomes with expression of molecular markers specified and others. Sufficient amount of biliary washings and tumor biopsies needed for analysis.</description>
        <time_frame>Once in the screening period (within 14 days of starting treatment)</time_frame>
        <population>Insufficient amount of patient samples collected for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Phenotypic Expression of NF-kB, p53, and Other Molecular Markers in Biliary Washings and Tumor Biopsies With Clinical Outcomes</title>
          <description>Evaluation of clinical outcomes with expression of molecular markers specified and others. Sufficient amount of biliary washings and tumor biopsies needed for analysis.</description>
          <population>Insufficient amount of patient samples collected for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Correlation of Treatment With Changes in Phenotypic Expression of Molecular Markers</title>
        <description>Phenotypic expression of molecular markers before and after study treatment</description>
        <time_frame>Duration of study treatment</time_frame>
        <population>Insufficient amount of patient samples collected for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of Treatment With Changes in Phenotypic Expression of Molecular Markers</title>
          <description>Phenotypic expression of molecular markers before and after study treatment</description>
          <population>Insufficient amount of patient samples collected for analysis</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>Clinical Benefit Rate</title>
        <description>Best response to study treatment was confirmed complete response, partial response, or stable disease. Unconfirmed partial response was not included. The outcome measure data table is stratified into patients who a) received prior therapy b) did not receive prior therapy.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.
bortezomib: Given IV</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Benefit Rate</title>
          <description>Best response to study treatment was confirmed complete response, partial response, or stable disease. Unconfirmed partial response was not included. The outcome measure data table is stratified into patients who a) received prior therapy b) did not receive prior therapy.</description>
          <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Patients who received prior therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patients who did not receive prior therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>6-Month Survival</title>
        <description>The time from initiation of therapy to 6 months beyond.</description>
        <time_frame>6 months</time_frame>
        <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>6-Month Survival</title>
          <description>The time from initiation of therapy to 6 months beyond.</description>
          <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>1-year Survival</title>
        <description>The time from initiation of initiation of therapy to 1 year beyond.</description>
        <time_frame>1 year</time_frame>
        <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>1-year Survival</title>
          <description>The time from initiation of initiation of therapy to 1 year beyond.</description>
          <population>1 patient who withdrew consent prior to the first disease evaluation was excluded.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>6-Month and 1-Year Survival for Patients Who Derived Clinical Benefit From Study Treatment</title>
        <description>The time from initiation of therapy to 6 months beyond. Only patients who derived benefit from study treatment (stable disease, partial response, or complete response was best response) were included.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Patients who derived benefit from study treatment (stable disease, partial response, or complete response was best response)</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>6-Month and 1-Year Survival for Patients Who Derived Clinical Benefit From Study Treatment</title>
          <description>The time from initiation of therapy to 6 months beyond. Only patients who derived benefit from study treatment (stable disease, partial response, or complete response was best response) were included.</description>
          <population>Patients who derived benefit from study treatment (stable disease, partial response, or complete response was best response)</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6-Month Survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Year Survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Post-Hoc</type>
        <title>6-Month and 1-Year Survival: Patients Who Did Not Derive Clinical Benefit From Study Treatment</title>
        <description>The time from initiation of therapy to 6 months beyond. Only patients who did not derive clinical benefit from study treatment (progressive disease or unconfirmed partial response was best response) were included.</description>
        <time_frame>Up to 1 year</time_frame>
        <population>Patients who did not derive clinical benefit from study treatment (progressive disease was best response) only.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm I</title>
            <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
          </group>
        </group_list>
        <measure>
          <title>6-Month and 1-Year Survival: Patients Who Did Not Derive Clinical Benefit From Study Treatment</title>
          <description>The time from initiation of therapy to 6 months beyond. Only patients who did not derive clinical benefit from study treatment (progressive disease or unconfirmed partial response was best response) were included.</description>
          <population>Patients who did not derive clinical benefit from study treatment (progressive disease was best response) only.</population>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6-Month Survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>1-Year Survival</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Arm I</title>
          <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>aseptic vasculitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>meningitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>renal insufficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>GI obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain (all sites)</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Elevated alkaline phosphatase</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated AST/ALT</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Elevated creatinine</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE 3.0">thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash/ulceration</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The trial was discontinued early due to no confirmed partial responses.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Assistant Professor, Medical Oncology</name_or_title>
      <organization>Fox Chase Cancer Center</organization>
      <phone>215-214-1676</phone>
      <email>crystal.denlinger@fccc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

